

Yusuke Hirota, MD, PhD

Department of Diabetology, Endocrinology
and Metabolism, Tokyo Medical University
Hachioji Medical Center, Tokyo, Japan

Takaya Matsushita, MD, PhD

Department of Diabetology, Endocrinology
and Metabolism, Tokyo Medical University
Hachioji Medical Center, Tokyo, Japan

Hyperpigmentation as a clue to Addison disease



Figure 1. Skin pigmentation in the patient's tongue (left) and on the soft palate (right).

A 66-YEAR-OLD WOMAN presented to our department with generalized fatigue and loss of appetite.

A review of her medical record showed that at age 52 she had undergone kidney transplant for end-stage kidney disease, receiving treatment of tacrolimus and mycophenolate after induction therapy with methylprednisolone 1,000 mg/day tapered over 3 months. After that, without steroids or antihypertensive drugs, her blood pressure had remained within the normal range. Mild hyperkalemia had been noted, and her fasting blood glucose was in the normal range.

On admission, her heart rate was 74 beats per minute and her blood pressure was 117/80 mm Hg. Physical examination revealed hyperpigmentation of

her tongue and soft palate (**Figure 1**), as well as the buccal mucosa, lower lip, fingers, and nail beds. The eyelids, neck, nipples, elbows, back, knees, and soles had very mild or no pigmentation. When asked about the hyperpigmentation, the patient said that she had first noticed it more than 20 years ago but that it had not interfered with her daily life, and she had never sought medical attention for it.

■ INITIAL WORKUP

Laboratory testing at admission showed the following:

- Potassium 5.7 mmol/L (reference range 3.6–4.8)
- Adrenocorticotropic hormone (ACTH) of 372 pg/mL (7.2–63.3)

doi:10.3949/ccjm.89a.21082

- Dehydroepiandrosterone sulfate 15 µg/dL (12–133)
- Estimated glomerular filtration rate of 33.2 mL/min/1.73 m² (≥ 60)
- Morning cortisol 8.93 µg/dL (6.24–18.00)
- 24-hour urinary free cortisol less than 12.5 µg/day (11.2–80.3)
- Plasma renin activity and plasma aldosterone concentration were normal
- Anti-adrenal antibody testing and cytomegalovirus antigenemia test were negative
- Rapid ACTH stimulation test showed no significant increase in serum cortisol.

Computed tomography of the abdomen showed no adrenal hyperplasia, nodules, or malignant lesions.

These findings and the results of laboratory testing supported the diagnosis of Addison disease. The patient received glucocorticoid-replacement therapy without mineralocorticoid, which relieved the hyponatremia, hyperkalemia, and general symptoms. One month after the start of replacement therapy, the hyperpigmentation had improved slightly.

■ CAUSES AND SYMPTOMS OF PRIMARY ADRENAL INSUFFICIENCY

Addison disease, or primary adrenal insufficiency, is an uncommon disease caused by destruction of the adrenal cortex, usually owing to an autoimmune process. Other causes include infections, malignant infiltration, metabolic dysfunction, and granulomatous disease, as well as genetic, neonatal, vascular, pharmacologic, neoplastic, and surgical factors.¹

Common clinical manifestations are fatigue, weight loss, orthostatic hypotension, skin and mucosal hyperpigmentation, nausea, vomiting, abdominal pain, libido reduction, depression, and salt-craving, depending on any deficiencies of glucocorticoids, mineralocorticoids, or androgens.^{1,2}

Most manifestations are nonspecific and slowly progressive, so the diagnosis of Addison disease is often difficult or delayed. However, hyperpigmentation, caused by excess binding of ACTH and

alpha-melanocyte stimulating hormone to the melanocortin 1 receptor,³ is a characteristic feature and a diagnostic clue for Addison disease.²

Diffuse hyperpigmentation is also caused by medications (eg, chemotherapeutic agents, antiarrhythmals, oral contraceptives, prostaglandin agonists, amiodarone, minocycline) and by endocrine and metabolic diseases (hyperthyroidism, diabetes mellitus, hemochromatosis).⁴ This patient was taking none of these agents, and there was no endocrine or metabolic disease present to produce hyperpigmentation other than Addison disease.

■ FEATURES OF HYPERPIGMENTATION OFFER DIAGNOSTIC CLUES

The characteristics of skin hyperpigmentation can offer clues to the cause. For example, aminoquinoline drugs can induce gray-blue pigmentation on pretibial surfaces, oral mucosa, sclera, and subungual areas. Minocycline induces 3 patterns: generalized brown discoloration, dark blue discoloration confined to acne scars or areas of skin inflammation, and gray-blue discoloration on the front of the lower extremities or in exposed areas. In Addison disease, hyperpigmentation is muddy and diffuse on buccal, conjunctival, and genital mucosa and on nail beds, palmar creases, and nipples.⁴

■ TAKE-HOME MESSAGE

When Addison disease is considered in the differential diagnosis, it is important to review the patient's medical history, to examine the skin and mucous membranes for hyperpigmentation, to measure early-morning plasma ACTH and serum cortisol, and to perform the ACTH stimulation test. Glucocorticoid and mineralocorticoid replacement therapy is essential. ■

■ DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

■ REFERENCES

1. **Betterle C, Presotto F, Furmaniak J.** Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults. *J Endocrinol Invest* 2019; 42(12):1407–1433. doi:10.1007/s40618-019-01079-6
2. **Bancos I, Hahner S, Tomlinson J, Arlt W.** Diagnosis and management of adrenal insufficiency. *Lancet Diabetes Endocrinol* 2015; 3(3):216–226. doi:10.1016/S2213-8587(14)70142-1
3. **Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R.** The melanocortin 1 receptor and the UV response of human melanocytes—a shift in paradigm. *Photochem Photobiol* 2008; 84(2):501–508. doi:10.1111/j.1751-1097.2008.00294.x
4. **Stulberg DL, Clark N, Tovey D.** Common hyperpigmentation disorders in adults: part I. Diagnostic approach, café au lait macules, diffuse hyperpigmentation, sun exposure, and phototoxic reactions. *Am Fam Physician* 2003; 68(10):1955–1960. PMID:14655804

Address: Yusuke Hirota, MD, PhD, Department of Diabetology, Endocrinology and Metabolism, Tokyo Medical University Hachioji Medical Center, 1163 Tate-machi, Hachioji-city, Tokyo 193-0998, Japan; hyusuke114@hotmail.co.jp